Navigation Links
Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism
Date:5/11/2015

RYE, N.Y., May 11, 2015 /PRNewswire/ -- Curemark LLC, a privately held drug research and development company, announced the start of a new Phase III double blind, randomized, placebo-controlled clinical trial to examine the effect of its novel formulation, CM-AT, on all children ages 3-8 with Autism. Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of the digestive enzyme chymotrypsin. This new trial will help determine whether all children with Autism could potentially benefit from CM-AT.

Dr. Joan Fallon, Curemark Founder and CEO stated, "From the beginning, our goal has been to bring our proprietary Autism drug to as many children with the condition as possible.  This trial has the potential to dramatically deepen our understanding around which children with Autism can benefit from CM-AT."

Curemark is currently submitting its rolling New Drug Application for CM-AT under the FDA's Fast Track designation.  A Fast Track designation is designed to help facilitate the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions that demonstrate the potential to meet unmet medical needs.

The company is initiating this trial at 20 centers of excellence for Autism throughout the United States. "We have chosen some of the pre-eminent clinical sites and clinicians to conduct this clinical trial," states Dr. Matthew Heil, Curemark's Chief Scientific Officer.

For a current list of clinical sites please go to www.clinicaltrials.gov

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for Autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com

Safe-Harbor Statements

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data
2. Guidepoint Launches Post-Surgical Pain Management TRACKER
3. Personal Data Protection Company Launches New Product
4. Marken Launches New Patient-Centric Campaign
5. NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet
6. FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015
7. BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout
8. Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain
9. Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner
10. Atmel Launches Industrys First Wide-V(cc) Low-Power Temperature Sensor Family
11. CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
Breaking Biology Technology: